FI962073A0 - HIV-proteaasin estäjän prodrug-muotoja - Google Patents
HIV-proteaasin estäjän prodrug-muotojaInfo
- Publication number
- FI962073A0 FI962073A0 FI962073A FI962073A FI962073A0 FI 962073 A0 FI962073 A0 FI 962073A0 FI 962073 A FI962073 A FI 962073A FI 962073 A FI962073 A FI 962073A FI 962073 A0 FI962073 A0 FI 962073A0
- Authority
- FI
- Finland
- Prior art keywords
- protease inhibitor
- hiv protease
- prodrug forms
- prodrug
- forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15420493A | 1993-11-18 | 1993-11-18 | |
| PCT/US1994/013085 WO1995014016A1 (en) | 1993-11-18 | 1994-11-14 | Prodrugs of an inhibitor of hiv protease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI962073A FI962073A (fi) | 1996-05-15 |
| FI962073A0 true FI962073A0 (fi) | 1996-05-15 |
Family
ID=22550424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI962073A FI962073A0 (fi) | 1993-11-18 | 1996-05-15 | HIV-proteaasin estäjän prodrug-muotoja |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5733907A (fi) |
| EP (1) | EP0729467A1 (fi) |
| JP (1) | JPH09505303A (fi) |
| KR (1) | KR960705809A (fi) |
| CN (1) | CN1139432A (fi) |
| AU (1) | AU687128B2 (fi) |
| CA (1) | CA2174649A1 (fi) |
| CZ (1) | CZ140696A3 (fi) |
| FI (1) | FI962073A0 (fi) |
| HU (1) | HUT76270A (fi) |
| IL (1) | IL111584A0 (fi) |
| NO (1) | NO962000D0 (fi) |
| NZ (1) | NZ276622A (fi) |
| PL (1) | PL314486A1 (fi) |
| SK (1) | SK61496A3 (fi) |
| WO (1) | WO1995014016A1 (fi) |
| ZA (1) | ZA949127B (fi) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6458772B1 (en) | 1909-10-07 | 2002-10-01 | Medivir Ab | Prodrugs |
| US20040122000A1 (en) | 1981-01-07 | 2004-06-24 | Vertex Pharmaceuticals Incorporated. | Inhibitors of aspartyl protease |
| US6878728B1 (en) | 1999-06-11 | 2005-04-12 | Vertex Pharmaceutical Incorporated | Inhibitors of aspartyl protease |
| MY126358A (en) * | 1996-03-22 | 2006-09-29 | Glaxo Group Ltd | Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs |
| US6436989B1 (en) | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| AU2012199A (en) * | 1997-12-24 | 1999-07-19 | Vertex Pharmaceuticals Incorporated | Prodrugs of aspartyl protease inhibitors |
| FR2773994B1 (fr) * | 1998-01-23 | 2002-10-11 | Univ Nice Sophia Antipolis | Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central |
| WO1999065870A2 (en) | 1998-06-19 | 1999-12-23 | Vertex Pharmaceuticals Incorporated | Sulfonamide inhibitors of aspartyl protease |
| US6319946B1 (en) | 1999-02-12 | 2001-11-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of aspartyl protease |
| IL150929A0 (en) * | 2000-01-28 | 2003-06-24 | Rohm & Haas | Pharmaceutical compounds comprising a pharmaceutically active moiety and a moiety comprising a substituent that enhances its properties |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7202092B2 (en) * | 2001-07-13 | 2007-04-10 | Roche Diagnostics Operations, Inc. | Indinavir derivatives useful in immunoassay |
| WO2003077902A1 (en) | 2002-02-19 | 2003-09-25 | Xenoport, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| US8603949B2 (en) * | 2003-06-17 | 2013-12-10 | California Institute Of Technology | Libraries of optimized cytochrome P450 enzymes and the optimized P450 enzymes |
| US7662987B2 (en) * | 2003-07-15 | 2010-02-16 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl compounds |
| PT1660440E (pt) | 2003-08-20 | 2012-05-15 | Xenoport Inc | Pró-fármacos de aciloxialquilcarbamato, métodos de síntese e utilização |
| WO2005066122A2 (en) | 2003-12-30 | 2005-07-21 | Xenoport, Inc. | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US541168A (en) * | 1895-06-18 | Frank e | ||
| GB1338169A (en) * | 1971-03-09 | 1973-11-21 | Smith Kline French Lab | Ureas thioureas and guanidines |
| US4144346A (en) * | 1977-01-31 | 1979-03-13 | Janssen Pharmaceutica N.V. | Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles |
| US4661473A (en) * | 1984-03-27 | 1987-04-28 | Merck & Co., Inc. | Renin inhibitors containing peptide isosteres |
| WO1989003842A1 (en) * | 1987-10-21 | 1989-05-05 | The Upjohn Company | Renin inhibitors containing a (1-amino-2-hydroxy-2-heterocyclic) ethyl moiety |
| DK24089D0 (da) * | 1989-01-20 | 1989-01-20 | Hans Bundgaard | Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups |
| US5218114A (en) * | 1991-04-10 | 1993-06-08 | Merck & Co., Inc. | Cholecystokinin antagonists |
| US5169952A (en) * | 1991-07-02 | 1992-12-08 | Merck & Co., Inc. | Stereoselective production of hydroxyamide compounds from chiral α-amino epoxides |
| US5413999A (en) * | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| IL103613A (en) * | 1991-11-08 | 1999-05-09 | Merck & Co Inc | VIH protease inhibitors, and the process of preparing intermediates and pharmaceutical preparations containing them. |
| US5463067A (en) * | 1993-07-16 | 1995-10-31 | Merck & Co., Inc. | Process for making HIV protease inhibitors |
| CZ293953B6 (cs) * | 1993-07-16 | 2004-08-18 | Mercká@Áco@Źáinc | Způsob výroby meziproduktů pro výrobu inhibitorů HIV@proteázy a příslušné meziprodukty |
| WO1995010281A1 (en) * | 1993-10-13 | 1995-04-20 | Merck & Co., Inc. | Combination therapy for hiv infection |
| US5455351A (en) * | 1993-12-13 | 1995-10-03 | Abbott Laboratories | Retroviral protease inhibiting piperazine compounds |
-
1994
- 1994-11-10 IL IL11158494A patent/IL111584A0/xx unknown
- 1994-11-14 HU HU9601340A patent/HUT76270A/hu unknown
- 1994-11-14 WO PCT/US1994/013085 patent/WO1995014016A1/en not_active Application Discontinuation
- 1994-11-14 CZ CZ961406A patent/CZ140696A3/cs unknown
- 1994-11-14 PL PL94314486A patent/PL314486A1/xx unknown
- 1994-11-14 EP EP95901884A patent/EP0729467A1/en not_active Withdrawn
- 1994-11-14 CN CN94194700A patent/CN1139432A/zh active Pending
- 1994-11-14 KR KR1019960702721A patent/KR960705809A/ko not_active Application Discontinuation
- 1994-11-14 JP JP7514536A patent/JPH09505303A/ja active Pending
- 1994-11-14 CA CA002174649A patent/CA2174649A1/en not_active Abandoned
- 1994-11-14 SK SK614-96A patent/SK61496A3/sk unknown
- 1994-11-14 NZ NZ276622A patent/NZ276622A/en unknown
- 1994-11-14 AU AU10960/95A patent/AU687128B2/en not_active Expired - Fee Related
- 1994-11-17 ZA ZA949127A patent/ZA949127B/xx unknown
-
1996
- 1996-03-27 US US08/622,945 patent/US5733907A/en not_active Expired - Fee Related
- 1996-05-15 NO NO962000A patent/NO962000D0/no unknown
- 1996-05-15 FI FI962073A patent/FI962073A0/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0729467A1 (en) | 1996-09-04 |
| HUT76270A (en) | 1997-07-28 |
| KR960705809A (ko) | 1996-11-08 |
| PL314486A1 (en) | 1996-09-16 |
| FI962073A (fi) | 1996-05-15 |
| US5733907A (en) | 1998-03-31 |
| IL111584A0 (en) | 1995-01-24 |
| SK61496A3 (en) | 1996-11-06 |
| CN1139432A (zh) | 1997-01-01 |
| NZ276622A (en) | 1997-09-22 |
| WO1995014016A1 (en) | 1995-05-26 |
| HU9601340D0 (en) | 1996-07-29 |
| JPH09505303A (ja) | 1997-05-27 |
| CA2174649A1 (en) | 1995-05-26 |
| NO962000L (no) | 1996-05-15 |
| NO962000D0 (no) | 1996-05-15 |
| AU1096095A (en) | 1995-06-06 |
| ZA949127B (en) | 1996-05-17 |
| AU687128B2 (en) | 1998-02-19 |
| CZ140696A3 (en) | 1996-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69434214D1 (de) | HIV protease inhibitoren | |
| NO306458B1 (no) | DP-IV-serin proteaseinhibitorer | |
| NO932620D0 (no) | Amindiol-proteaseinhibitorer | |
| NO954427D0 (no) | Hiv-proteaseinhibitorer som er anvendbare for behandling av AIDS | |
| PT885887E (pt) | Inibidores de sulfonamida de aspartil-protease de hiv | |
| FI893962A0 (fi) | Vid vaord av aids anvaendbara hiv-proteas -inhibitorer. | |
| FI962073A0 (fi) | HIV-proteaasin estäjän prodrug-muotoja | |
| PH31249A (en) | Inhibitors of hiv protease. | |
| FI943234A0 (fi) | Ihmisen Kunitz-tyyppisen proteaasiestäjän muunnos | |
| FI923158A (fi) | Hiv-proteas-inhibitorer anvaendbara vid behandling av aids | |
| FI935644A (fi) | Retrovirusten proteaasi-inhibiittoreita | |
| FI932847A (fi) | Hiv-proteasinhibitorer som aer anvaendbara foer behandling av aids | |
| MX9100121A (es) | Inhibidores de proteasas asparticas | |
| DE69312093D1 (de) | Prodrug von entzündungshemmenden 3-acyl-2-oxindol-1-carboxamiden | |
| KR950003975U (ko) | 열쇠의 표식구 | |
| NO920023L (no) | Hiv-proteaseinhibitorer | |
| MX9204259A (es) | Compuestos inhibidores de proteasa retroviral. | |
| NO994415L (no) | HIV proteaseinhibitorer | |
| SE9501466D0 (sv) | Antiviral protease inhibition | |
| SI0774969T1 (en) | Hiv protease inhibitor combination |